Back to top
more

Charles River Laboratories International (CRL)

(Delayed Data from NYSE)

$295.10 USD

295.10
1,231,097

-2.54 (-0.85%)

Updated Aug 26, 2026 04:00 PM ET

After-Market: $295.07 -0.03 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 247)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Charles River (CRL) Extends Gene Therapy Deal With NUS Medicine

by Zacks Equity Research

Charles River (CRL) announces the extension of the gene therapy manufacturing alliance with NUS Medicine.

Zacks Equity Research

Why Is Charles River (CRL) Up 6.2% Since Last Earnings Report?

by Zacks Equity Research

Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Charles River (CRL) Extends Gene Therapy Offering With New Pact

by Zacks Equity Research

Charles River's (CRL) partnership with Navega Therapeutics will enable it to leverage its strong AAV portfolio and leading gene therapy CDMO capabilities.

Zacks Equity Research

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Investors remain optimistic about Charles River (CRL) due to the strength of the RMS segment.

Zacks Equity Research

Charles River (CRL) Forges Collaboration With Wheeler Bio

by Zacks Equity Research

Charles River (CRL) and Wheeler Bio join forces to accelerate the journey from discovery and CMC development to manufacturing.

Zacks Equity Research

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Charles River (CRL) Gains From CRADL Amid Soft Market Scenario

by Zacks Equity Research

Within DSA, Charles River (CRL) is currently the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide.

Zacks Equity Research

Charles River (CRL) Q4 Earnings Surpass, Margins Contract

by Zacks Equity Research

Charles River (CRL) delivers better-than-expected revenues and earnings in the fourth quarter of 2023.

Zacks Equity Research

Charles River (CRL) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Charles River's (CRL) share price is likely to grow, backed by the strength of the RMS segment.